OPTiM Oncovex GM-CSF Phase 3 trial in melanoma

BioVex Inc Logo

Testing a New Approach in Advanced Melanoma

OPTiM - Testing a New Approach in Advanced Melanoma. OPTiM is a Phase 3 clinical study evaluating a new investigational agent called OncoVEXGM-CSF.
            
            
            
Image © iStockphoto.com

Clinical trials are scientific research studies designed to find better ways to treat or prevent diseases. Whether you are a patient or a caregiver, our goal for this Web site is to answer your questions and help you understand the trial experience.

OPTiM is a Phase 3 clinical study evaluating a new investigational agent called
OncoVEXGM-CSF

OncoVEXGM-CSF is now being tested to see if it can provide an effective treatment for people with melanoma. It is an investigational agent, which means it has not been approved by the Food and Drug Administration (FDA) for marketing.

You are invited to explore our website; or, click here to obtain further information about how to participate in the trial.

If you have advanced melanoma consider enrolling in the OPTiM trial
Copyright © BioVex 2009 legal notice